GlassScriptPhysician profile
Austin Walker Harrison
NPI 1356187553
$3,528.62
in general payments reported to CMS, 2019-2025
19 companies · $2,811 in 2025
The $2,811 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $717 · 2025: $2,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,521 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,521.10 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $600.20 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $502.09 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $349.05 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.67 | 2024-2025 | Caplyta |
| Abbvie INC. | $315.95 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $286.61 | 2024-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $226.94 | 2024-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $186.77 | 2025 | Qelbree |
| Axsome Therapeutics, INC. | $127.95 | 2025 | Auvelity |
| Corium, LLC | $109.93 | 2024-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $82.25 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Collegium Pharmaceutical, INC. | $72.08 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $66.59 | 2025 | |
| Tris Pharma INC | $59.08 | 2024-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $55.96 | 2025 | Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $54.39 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $48.94 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.15 | 2024 | |
| Indivior INC. | $27.02 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.